As global trade tensions escalate, Asian markets have faced significant volatility, with investors closely monitoring the economic impacts of ongoing tariff disputes. Amidst this uncertainty, ...

Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.

The collective net worth of Korea’s 50 Richest on the 2025 Forbes list fell to US$99 billion from $115 billion last year.

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to acquire antibody-drug conjugate expert Araris Biotech. WuXi AppTec ...

Here we highlight a subset of our preferred stocks from the screener. Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary ...

Three newcomers buck the trend, including Kim Jung-soo & Chun In-jang, the couple behind spicy Buldak noodles.

Here we highlight a subset of our preferred stocks from the screener. Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

S. Korean market plunges as Trumps tariff threat spreads globally KOSPI sinks 4.4% as panic selling hits Seoul ...

South Korea-based drugmaker Alteogen (196170.KQ), opens new tab is developing and manufacturing an enzyme used with the subcutaneous formulation of Keytruda. "We believe we have a very strong ...